Late June and early July have been characterized by a clutch of initial public offerings from biopharmaceutical companies, with three others filing plans to go public as well.
Before the Independence Day fireworks, Dova Pharmaceuticals Inc. CEO Alex Sapir rang the Nasdaq opening bell following a June 28 IPO that brought in $75.1m with an offering of over 4.4 million shares priced at $17 each
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?